An anonymous director reports

AVICANNA SUBSIDIARY SMGH COMPLETES FIRST COMMERCIAL EXPORT TO AUSTRALIA

Through Avicanna Inc.'s majority-owned subsidiary, Santa Marta Golden Hemp SAS (SMGH), the company completed its first commercial export of CBG-dominant cannabis flower to Australia.

Over the past two years, Avicanna has invested in process development, infrastructure and quality systems to align SMGH's operations with international regulatory expectations for active pharmaceutical ingredients (API) and raw materials. As a result, SMGH is positioned to produce consistent, standardized cannabis flower at commercial scale, with a focus on cannabinoid-specific chemotypes, traceability, and compliance with Good Agricultural and Collection Practices (GACP) and organic certification standards.

SMGH's operational model incorporates several structural strengths relevant to cultivation and production of cannabinoid API including year-round cultivation enabled by equatorial conditions, controlled environmental parameters and established genetic portfolios registered in Colombia. These factors contribute toward supporting conditions for consistent production cycles, batch uniformity and cost-efficiencies, which are essential for long-term participation in international medical cannabis markets.

This export also includes SMGH's proprietary CBG cultivar, part of the company's portfolio of registered varieties. With this shipment, SMGH has now supplied products into 21 international markets and Avicanna products have reached 24 markets globally, reflecting the company's experience navigating complex regulatory frameworks.

Avicanna carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About Aureus

The Aureus brand is the company's line of raw materials and active pharmaceutical ingredients, including CBD, CBG and THC manufactured through SMGH. The cannabis raw materials supplied by SMGH, form part of the company's supply chain and reliable input for its consumer retail, medical cannabis, and pharmaceutical preparations and pipeline globally.

SMGH is also dedicated to providing consistent, high-quality sources of input materials to the various companies operating in a variety of industries internationally. SMGH received Good Agricultural, and Collection Practices (GACP) and organic certifications under the United States Department of Agriculture National Organic Program (USDA) for its hemp cultivars. SMGH has exported Aureus branded products into 20 different countries for research and manufacturing purposes. The SMGH facility contains approximately 300,000 square feet of cultivation space with an extraction capacity of 300 kilograms. The current annual yield is approximately 26,400 kg.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D (research and development) and clinical development leading to the commercialization of more than 30 proprietary, evidence-based finished products and supporting four commercial stage business pillars.

• Medical cannabis formulary (RHO Phyto): The formulary offers a diverse range of proprietary products including oral, sublingual, topical and transdermal deliveries with varying ratios of cannabinoids, supported by continuing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the medical cannabis patients' journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
• Pharmaceutical pipeline: Leveraging Avicanna's scientific platform, vertical integration and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain and various neurological disorders.
• Active pharmaceutical ingredients (Aureus Santa Marta): Active pharmaceutical ingredients supplied by the company's majority owned subsidiary, Santa Marta Golden Hemp SAS (SMGH), is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the company's international partners for use in the development and production of food, cosmetics, medical and pharmaceutical products. SMGH also forms part of the company's supply chain and is a source of reliable input products for its consumer retail, medical cannabis and pharmaceutical products globally.

We seek Safe Harbor.